This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wiernikowski, J. Articles by Atkinson, S. Search for Related Content PubMed PubMed Citation Articles by Wiernikowski, J. Articles by Atkinson, S. Social Bookmarking                         What's this?

Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin’s lymphoma: results of a pilot study

McMaster Children’s Hospital, Hamilton, Ont., Canada

RD Barr, MD

McMaster Children’s Hospital, Hamilton, Ont., Canada, Department of Pediatrics, McMaster University, Hamilton, Ont., Canada

C Webber, PhD

Department of Nuclear Medicine, Hamilton Health Sciences, Hamilton, Ont., Canada

CY Guo, PhD

Department of Pediatrics, McMaster University, Hamilton, Ont., Canada

M Wright, BSc PT, MEd

McMaster Children’s Hospital, Hamilton, Ont., Canada, Department of Pediatrics, McMaster University, Hamilton, Ont., Canada

SA Atkinson, PhD

McMaster Children’s Hospital, Hamilton, Ont., Canada, Department of Pediatrics, McMaster University, Hamilton, Ont., Canada

Background/objectives. Osteopenia is a significant morbidity in children undergoing therapy for acute lymphoblastic leukaemia (ALL) or non-Hodgkin’s lymphoma (NHL). We conducted a pilot study to assess the impact of alendronate on whole body bone mineral content (WB-BMC), lumbar spine bone mineral density (LS-BMD), biochemical measures of bone mineral metabolism, as well as gross motor function and health-related quality of life (HRQL) in children undergoing therapy for ALL or NHL.

Methods. Ten children (nine boys) between the ages of 3.6 and 14.6 years, on identical maintenance chemotherapy for ALL or NHL were treated with oral alendronate once weekly, and daily calcium supplementation, for a period of six months. Outcome measures were WB-BMC and LSBMD; biochemical measures of bone mineral metabolism including plasma osteocalcin, C-terminal telopeptide of type I collagen (CTx), serum calcium, 25-hydroxy-vitamin D (25-OHD), and parathyroid hormone (PTH); as well as assessments of motor function and HRQL.

Results. A gain in Z score was observed in 7/9 evaluable patients for WB-BMC (mean increase of 0.49) and LS-BMD (0.51). Plasma osteocalcin and CTx showed a change in bone turnover favouring formation over resorption. Serum calcium and 25- OHD remained normal throughout treatment. After an initial spike, serum PTH returned to baseline values at week 4. Measures of motor function showed some improvement and there were modest gains in HRQL.

Conclusions. Alendronate therapy was tolerated well. Further study in a larger sample of children with ALL or NHL is warranted, in the context of a randomized clinical trial.

Key Words: acute lymphoblastic leukaemia (ALL) • bisphosphonates • morbidity • osteopenia • paediatrics • quality of life

Journal of Oncology Pharmacy Practice, Vol. 11, No. 2, 51-56 (2005)
DOI: 10.1191/1078155205jp145oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. L Bryant, M. A Worthington, and K. Parsons Treatment of Osteoporosis/Osteopenia in Pediatric Leukemia and Lymphoma Ann. Pharmacother., April 1, 2009; 43(4): 714 - 720. [Abstract] [Full Text] [PDF]